Versions Compared
Key
- This line was added.
- This line was removed.
- Formatting was changed.
Cancer Synoptic Reporting Project Group
1 November at
1716:30 UTC
Attendees
Apologies
Meeting Recording (GoogleDrive)
https://drive.google.com/file/d/14dkEwspPXIqEoSZNcg6XW66xvRkLYK3v/view?usp=sharing
Discussion items
| Item | Description | Owner | Notes | Action | |
|---|---|---|---|---|---|
| 1 | Status of initial sub |
| |||
| 2 | Intactness/quality of specimen concepts |
| Approach agreed upon. Create new concept |Anatomic integrity (property)|. When used with |Inheres in| = some (specimen), then the discussion is about the anatomic integrity of the specimen which is appropriate for CSRWG observations.
| ||
| 3 | Mitotic rate |
| number cell in Cell division phase phase/total count of cells in a normalized area
2. Ki-67=> proliferation fraction...# cells expressing ?/total count in a specific area mitotic cell state/resting state | ||
| 4 | Metastasis observable | Inclusion of primary tumor site in observable as |Inherent location| in metastatic spread observables Review sample concept | So far, so good. More to model and synchronize with morphologic abnormality plan for primary/secondary neoplasm. | ||
| 5 | Tumor Deposit | Review model for colon and appendix Discuss with # of Tumor Deposits | |||
| 6 | Microsatellites/tumor nodules | Melanoma | |||
| 7 | Tumor descriptions | Tumor description (adrenal); Rhabdoid; Sarcomatoid (kidney); histologic patterns (lung) | These are dedifferentiation descriptors. Need to review ICD-O-3.2 to see if they are histologic subtypes vs. structural/proliferation/differentiation description | ||
| 8 | Lymph node locations/stations | Discuss approach to lymph node body structures and differences in naming/locations (example AJCC esophageal cancer vs. JES esophageal cancer) | |||
| 9 | IHC | Model review and discussion ER, PR, Her2, Ki-67, PD-L1, MLH1, PMS2, MSH2, MSH6,ATRX expression, Beta-catenin expression, reticulin How are these broken out/logically organized? Nuclear proteins? Cytoplasmic: Receptors? | |||
| 10 | Communication to users | Strategies to communicate work products? | Did not discuss | ||
| 11 | Tumor Staging | Discussed use of TNM-category levels.... | AJCC wants SI to eliminate all TNM content from terminology. Daniel Karlsson to discuss at member forum next week (26-10-2021) What are use cases? CDSS, research, electronic data exchange between systems... |
Meeting Files
| Attachments |
|---|
Previous Meetings
| Content Report Table | ||||||||
|---|---|---|---|---|---|---|---|---|
|